Autolus Therapeutics and Noile-Immune Announce Licensing Agreement
November 13 2019 - 6:30AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, and Noile-Immune Biotech, Inc., Tokyo, Japan, a
biotechnology company focusing on the development of innovative
cancer immunotherapies, today announced that they have entered into
a license agreement whereby Autolus will have the right to develop
CAR T cell therapies incorporating Noile-Immune’s PRIME
(proliferation-inducing and migration-enhancing) technology
secreting both IL-7 and CCL19. The PRIME technology is designed to
improve proliferation and trafficking into solid tumors of both
engineered CAR T cells as well as the patient’s own T cells.
Through the license agreement with Noile-Immune,
Autolus has gained the right to incorporate the PRIME technology in
its CAR T cell programs against a limited number of cancer targets.
Autolus will make an upfront cash payment and milestone payments to
Noile‑Immune, and Noile-Immune is also entitled to receive
royalties on net sales of resulting products. Additional terms of
the agreement were not disclosed.
“We have an emerging pipeline of CAR T cell
products targeting solid tumors and are excited to add the
Noile-Immune PRIME technology to our existing suite of T cell
programming modules,” said Dr. Christian Itin, chairman and chief
executive officer of Autolus. “We believe the PRIME
technology will help enhance the anti-tumor potential of CAR T
cells and expand our ability to design and develop transformational
CAR T therapies in a variety of solid tumor indications.”
“Autolus is a leader in the CAR T field, and we
are very pleased that they have selected our PRIME technology for
their solid tumor pipeline,” said Hidenobu Ishizaki, M.D., Ph.D.,
president & chief executive officer of Noile-Immune. “This
agreement provides further endorsement of our technologies, which
were invented by Dr. Koji Tamada, our scientific founder. We
look forward to continuing to contribute to, and develop, therapies
that have the potential to transform the lives of patients.”
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular
T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more
information please visit www.autolus.com.
About Noile-Immune Noile-Immune
Biotech, Inc., based in Tokyo, Japan, is a biotechnology company
focused on the development and commercialization of novel cancer
immunotherapy products with breakthrough technology to eradicate
cancer cells. The company aims to discover and develop innovative
cancer immunotherapies through the partnerships with experts in
academia including Yamaguchi University and The National Cancer
Center Japan, and deliver the best-in-class therapies to patients
as well. For more information, please visit
https://www.noile-immune.com/english/home/.
Forward-Looking StatementThis
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
statements that are not historical facts, and in some cases can be
identified by terms such as "may," "will," "could," "expects,"
"plans," "anticipates," and "believes." These statements include,
but are not limited to, statements regarding Autolus’ financial
condition and results of operations, as well as statements
regarding the anticipated development of Autolus’ product
candidates, including its intentions regarding the timing for
providing further updates on the development of its product
candidates, and the sufficiency of its cash resources. Any
forward-looking statements are based on management's current views
and assumptions and involve risks and uncertainties that could
cause actual results, performance or events to differ materially
from those expressed or implied in such statements. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed
on November 23, 2018 as well as discussions of potential risks,
uncertainties, and other important factors in Autolus' future
filings with the Securities and Exchange Commission from time to
time. All information in this press release is as of the date of
the release, and the company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events, or otherwise, except as required by
law.
Autolus Investor and media contact: Silvia
TaylorVice President, Corporate Affairs and Communications
Autolus+1-240-801-3850s.taylor@autolus.com
UK:Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com
Noile-Immune contact: Tsutom TokashikiSenior
Vice President, Business Noile-Immune
Biotechir@noile-immune.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024